Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 606

1.

Cytogenetic abnormalities in monoclonal gammopathy of undetermined significance.

Merz M, Hielscher T, Hoffmann K, Seckinger A, Hose D, Raab MS, Hillengass J, Jauch A, Goldschmidt H.

Leukemia. 2018 Jul 6. doi: 10.1038/s41375-018-0202-1. [Epub ahead of print] No abstract available.

PMID:
29977018
2.

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.

Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, Morgan G.

Leukemia. 2018 Jul 2. doi: 10.1038/s41375-018-0196-8. [Epub ahead of print]

PMID:
29967379
3.

Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma.

Mai EK, Hielscher T, Bertsch U, Schlenzka J, Salwender HJ, Munder M, Gerecke C, Dührsen U, Brossart P, Neben K, Hillengass J, Raab MS, Merz M, Baertsch MA, Jauch A, Hose D, Martin H, Lindemann HW, Blau IW, Scheid C, Weisel KC, Goldschmidt H; German-speaking Myeloma Multicenter Group (GMMG).

Leukemia. 2018 Jun 29. doi: 10.1038/s41375-018-0195-9. [Epub ahead of print] No abstract available.

PMID:
29959413
4.

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.

Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, Morgan GJ.

Blood. 2018 Jun 8. pii: blood-2018-03-840132. doi: 10.1182/blood-2018-03-840132. [Epub ahead of print]

PMID:
29884741
5.

Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN).

Larocca A, Dold SM, Zweegman S, Terpos E, Wäsch R, D'Agostino M, Scheubeck S, Goldschmidt H, Gay F, Cavo M, Ludwig H, Straka C, Bringhen S, Auner HW, Caers J, Gramatzki M, Offidani M, Dimopoulos MA, Einsele H, Boccadoro M, Sonneveld P, Engelhardt M.

Leukemia. 2018 Apr 25. doi: 10.1038/s41375-018-0142-9. [Epub ahead of print] Review.

PMID:
29880892
6.

Going the distance: Are we losing patients along the multiple myeloma treatment pathway?

Terpos E, Suzan F, Goldschmidt H.

Crit Rev Oncol Hematol. 2018 Jun;126:19-23. doi: 10.1016/j.critrevonc.2018.03.021. Epub 2018 Mar 29. Review.

PMID:
29759561
7.

Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma.

Kumar S, Durie B, Nahi H, Vij R, Dimopoulos MA, Kastritis E, Terpos E, Leleu X, Beksac M, Goldschmidt H, Hillengass J, Su Z, Hutton B, Cameron C, Khan I, Lam A.

Leuk Lymphoma. 2018 May 9:1-9. doi: 10.1080/10428194.2018.1459609. [Epub ahead of print]

PMID:
29741423
8.

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.

Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos MA, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos MV, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk NWCJ, Waage A, Beksac M, Mellqvist UH, Engelhardt M, Caers J, Driessen C, Bladé J, Sonneveld P.

Leukemia. 2018 May 2. doi: 10.1038/s41375-018-0040-1. [Epub ahead of print] Review.

9.

[Long-term follow-up of monoclonal gammopathies of undetermined significance (MGUS)].

Goldschmidt H, Nitschmann S.

Internist (Berl). 2018 Jun;59(6):639-640. doi: 10.1007/s00108-018-0425-2. German. No abstract available.

PMID:
29696302
10.

The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression.

Ali M, Ajore R, Wihlborg AK, Niroula A, Swaminathan B, Johnsson E, Stephens OW, Morgan G, Meissner T, Turesson I, Goldschmidt H, Mellqvist UH, Gullberg U, Hansson M, Hemminki K, Nahi H, Waage A, Weinhold N, Nilsson B.

Nat Commun. 2018 Apr 25;9(1):1649. doi: 10.1038/s41467-018-04082-2.

11.

Assessment of glucose metabolism and cellular proliferation in multiple myeloma: a first report on combined 18F-FDG and 18F-FLT PET/CT imaging.

Sachpekidis C, Goldschmidt H, Kopka K, Kopp-Schneider A, Dimitrakopoulou-Strauss A.

EJNMMI Res. 2018 Apr 10;8(1):28. doi: 10.1186/s13550-018-0383-7.

12.

Oncogene-induced senescence: a potential breakpoint mechanism against malignant transformation in plasma cell disorders.

Lehners N, Ellert E, Xu J, Hillengass J, Leichsenring J, Stenzinger A, Goldschmidt H, Andrulis M, Raab MS.

Leuk Lymphoma. 2018 Apr 4:1-10. doi: 10.1080/10428194.2018.1443450. [Epub ahead of print]

PMID:
29616856
13.

Platelet Count before Peripheral Blood Stem Cell Mobilization Is Associated with the Need for Plerixafor But Not with the Collection Result.

Baertsch MA, Kriegsmann K, Pavel P, Bruckner T, Hundemer M, Kriegsmann M, Ho AD, Goldschmidt H, Wuchter P.

Transfus Med Hemother. 2018 Jan;45(1):24-31. doi: 10.1159/000478911. Epub 2017 Oct 4.

14.

Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma.

Kriegsmann K, Dittrich T, Neuber B, Awwad MHS, Hegenbart U, Goldschmidt H, Hillengass J, Hose D, Seckinger A, Müller-Tidow C, Ho AD, Schönland S, Hundemer M.

Cytometry B Clin Cytom. 2018 Mar 25. doi: 10.1002/cyto.b.21636. [Epub ahead of print]

PMID:
29577600
15.

A systematic classification of death causes in multiple myeloma.

Mai EK, Haas EM, Lücke S, Löpprich M, Kunz C, Pritsch M, Knaup-Gregori P, Raab MS, Schlenzka J, Bertsch U, Hillengass J, Goldschmidt H.

Blood Cancer J. 2018 Mar 8;8(3):30. doi: 10.1038/s41408-018-0068-5. No abstract available.

16.

DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells.

Bruyer A, Maes K, Herviou L, Kassambara A, Seckinger A, Cartron G, Rème T, Robert N, Requirand G, Boireau S, Müller-Tidow C, Veyrune JL, Vincent L, Bouhya S, Goldschmidt H, Vanderkerken K, Hose D, Klein B, De Bruyne E, Moreaux J.

Br J Cancer. 2018 Apr;118(8):1062-1073. doi: 10.1038/s41416-018-0025-x. Epub 2018 Mar 2.

PMID:
29500406
17.

Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome.

Gu C, Holman C, Sompallae R, Jing X, Tomasson M, Hose D, Seckinger A, Zhan F, Tricot G, Goldschmidt H, Yang Y, Janz S.

Blood Cancer J. 2018 Feb 15;8(2):22. doi: 10.1038/s41408-018-0060-0. No abstract available.

18.

Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials.

Mateos MV, Goldschmidt H, San-Miguel J, Mikhael J, DeCosta L, Zhou L, Obreja M, Blaedel J, Szabo Z, Leleu X.

Hematol Oncol. 2018 Apr;36(2):463-470. doi: 10.1002/hon.2499. Epub 2018 Feb 15.

PMID:
29446103
19.

Cytogenetic aberrations in multiple myeloma are associated with shifts in serum immunoglobulin isotypes distribution and levels.

Yadav P, Merz M, Mai EK, Försti A, Jauch A, Goldschmidt H, Hemminki K.

Haematologica. 2018 Apr;103(4):e162-e164. doi: 10.3324/haematol.2017.184226. Epub 2018 Feb 1. No abstract available.

20.

Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma.

Garderet L, Iacobelli S, Koster L, Goldschmidt H, Johansson JE, Bourhis JH, Krejci M, Leleu X, Potter M, Blaise D, Koenecke C, Peschel C, Radocha J, Metzner B, Lenain P, Schäfer-Eckart K, Pohlreich D, Grasso M, Caillot D, Einsele H, Ladetto M, Schönland S, Kröger N.

Biol Blood Marrow Transplant. 2018 Jul;24(7):1372-1378. doi: 10.1016/j.bbmt.2018.01.035. Epub 2018 Feb 3.

PMID:
29408334
21.

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.

Merz M, Jauch A, Hielscher T, Bochtler T, Schönland SO, Seckinger A, Hose D, Bertsch U, Neben K, Raab MS, Hillengass J, Salwender H, Blau IW, Lindemann HW, Schmidt-Wolf IGH, Scheid C, Haenel M, Weisel KC, Goldschmidt H.

Blood Adv. 2017 Dec 27;2(1):1-9. doi: 10.1182/bloodadvances.2017013334. eCollection 2018 Jan 9.

22.

Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.

Siegel DS, Dimopoulos MA, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A, San-Miguel J, Obreja M, Blaedel J, Stewart AK.

J Clin Oncol. 2018 Mar 10;36(8):728-734. doi: 10.1200/JCO.2017.76.5032. Epub 2018 Jan 17.

PMID:
29341834
23.

Direct evidence for a polygenic etiology in familial multiple myeloma.

Halvarsson BM, Wihlborg AK, Ali M, Lemonakis K, Johnsson E, Niroula A, Cibulskis C, Weinhold N, Försti A, Alici E, Langer C, Pfreundschuh M, Goldschmidt H, Mellqvist UH, Turesson I, Waage A, Hemminki K, Golub T, Nahi H, Gullberg U, Hansson M, Nilsson B.

Blood Adv. 2017 Apr 7;1(10):619-623. doi: 10.1182/bloodadvances.2016003111. eCollection 2017 Apr 11.

24.

Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation: impact of clinical risk factors and sustained response.

Lehners N, Becker N, Benner A, Pritsch M, Löpprich M, Mai EK, Hillengass J, Goldschmidt H, Raab MS.

Cancer Med. 2018 Feb;7(2):307-316. doi: 10.1002/cam4.1283. Epub 2017 Dec 28.

25.

Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network.

Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos MA, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos MV, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk NWCJ, Waage A, Beksac M, Mellqvist UH, Engelhardt M, Caers J, Driessen C, Sonneveld P.

Leukemia. 2017 Dec 18. doi: 10.1038/leu.2017.353. [Epub ahead of print] Review.

26.

BioSITe: A Method for Direct Detection and Quantitation of Site-Specific Biotinylation.

Kim DI, Cutler JA, Na CH, Reckel S, Renuse S, Madugundu AK, Tahir R, Goldschmidt HL, Reddy KL, Huganir RL, Wu X, Zachara NE, Hantschel O, Pandey A.

J Proteome Res. 2018 Feb 2;17(2):759-769. doi: 10.1021/acs.jproteome.7b00775. Epub 2017 Dec 28.

PMID:
29249144
27.

Functional Imaging with 18F-FDG PET/CT and Diffusion Weighted Imaging (DWI) in Early Response Evaluation of Combination Therapy of Elotuzumab, Lenalidomide, and Dexamethasone in a Relapsed Multiple Myeloma Patient.

Sachpekidis C, Dimitrakopoulou-Strauss A, Delorme S, Goldschmidt H.

Diagnostics (Basel). 2017 Dec 15;7(4). pii: E61. doi: 10.3390/diagnostics7040061.

28.

CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma.

Alaterre E, Raimbault S, Goldschmidt H, Bouhya S, Requirand G, Robert N, Boireau S, Seckinger A, Hose D, Klein B, Moreaux J.

Oncotarget. 2017 Oct 30;8(58):98931-98944. doi: 10.18632/oncotarget.22131. eCollection 2017 Nov 17.

29.

Lenalidomide overcomes the immunosuppression of regulatory CD8+CD28- T-cells.

Neuber B, Dai J, Waraich WA, Awwad MHS, Engelhardt M, Schmitt M, Medenhoff S, Witzens-Harig M, Ho AD, Goldschmidt H, Hundemer M.

Oncotarget. 2017 Oct 5;8(58):98200-98214. doi: 10.18632/oncotarget.21516. eCollection 2017 Nov 17.

30.

From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives.

Gay F, Engelhardt M, Terpos E, Wäsch R, Giaccone L, Auner HW, Caers J, Gramatzki M, van de Donk N, Oliva S, Zamagni E, Garderet L, Straka C, Hajek R, Ludwig H, Einsele H, Dimopoulos M, Boccadoro M, Kröger N, Cavo M, Goldschmidt H, Bruno B, Sonneveld P.

Haematologica. 2018 Feb;103(2):197-211. doi: 10.3324/haematol.2017.174573. Epub 2017 Dec 7. Review.

31.

Prognostic significance of tumor burden assessed by whole-body magnetic resonance imaging in multiple myeloma patients treated with allogeneic stem cell transplantation.

Mosebach J, Shah S, Delorme S, Hielscher T, Goldschmidt H, Schlemmer HP, Schönland S, Hegenbart U, Hillengass J.

Haematologica. 2018 Feb;103(2):336-343. doi: 10.3324/haematol.2017.176073. Epub 2017 Dec 7.

32.

[Multiple myeloma : What has been confirmed in therapy?]

Baertsch MA, Goldschmidt H.

Internist (Berl). 2017 Dec;58(12):1250-1257. doi: 10.1007/s00108-017-0337-6. Review. German.

PMID:
29098319
33.

Body fat composition as predictive factor for treatment response in patients with newly diagnosed multiple myeloma - subgroup analysis of the prospective GMMG MM5 trial.

GroΔ JP, Nattenmüller J, Hemmer S, Tichy D, Krzykalla J, Goldschmidt H, Bertsch U, Delorme S, Kauczor HU, Hillengass J, Merz M.

Oncotarget. 2017 Jul 25;8(40):68460-68471. doi: 10.18632/oncotarget.19536. eCollection 2017 Sep 15.

34.

Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study.

Goldschmidt H, Moreau P, Ludwig H, Niesvizky R, Chng WJ, Joshua D, Weisel K, Spencer A, Orlowski RZ, Feng S, Iskander KS, Dimopoulos MA.

Leuk Lymphoma. 2018 Jun;59(6):1364-1374. doi: 10.1080/10428194.2017.1376743. Epub 2017 Sep 22.

PMID:
28937327
35.

Quantitative analysis of 18F-NaF dynamic PET/CT cannot differentiate malignant from benign lesions in multiple myeloma.

Sachpekidis C, Hillengass J, Goldschmidt H, Anwar H, Haberkorn U, Dimitrakopoulou-Strauss A.

Am J Nucl Med Mol Imaging. 2017 Sep 1;7(4):148-156. eCollection 2017.

36.

Genetic Predisposition to Multiple Myeloma at 5q15 Is Mediated by an ELL2 Enhancer Polymorphism.

Li N, Johnson DC, Weinhold N, Kimber S, Dobbins SE, Mitchell JS, Kinnersley B, Sud A, Law PJ, Orlando G, Scales M, Wardell CP, Försti A, Hoang PH, Went M, Holroyd A, Hariri F, Pastinen T, Meissner T, Goldschmidt H, Hemminki K, Morgan GJ, Kaiser M, Houlston RS.

Cell Rep. 2017 Sep 12;20(11):2556-2564. doi: 10.1016/j.celrep.2017.08.062.

37.

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.

Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R, Weisel K, Hungria V, Minuk L, Feng S, Zahlten-Kumeli A, Kimball AS, Moreau P.

Lancet Oncol. 2017 Oct;18(10):1327-1337. doi: 10.1016/S1470-2045(17)30578-8. Epub 2017 Aug 23.

PMID:
28843768
38.

Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group.

Hillengass J, Moulopoulos LA, Delorme S, Koutoulidis V, Mosebach J, Hielscher T, Drake M, Rajkumar SV, Oestergaard B, Abildgaard N, Hinge M, Plesner T, Suehara Y, Matsue K, Withofs N, Caers J, Waage A, Goldschmidt H, Dimopoulos MA, Lentzsch S, Durie B, Terpos E.

Blood Cancer J. 2017 Aug 25;7(8):e599. doi: 10.1038/bcj.2017.78.

39.

Therapeutic monoclonal antibodies in combination with pomalidomide can overcome refractoriness to both agents in multiple myeloma: A case-based approach.

Baertsch MA, Hundemer M, Hillengass J, Goldschmidt H, Raab MS.

Hematol Oncol. 2018 Feb;36(1):258-261. doi: 10.1002/hon.2473. Epub 2017 Aug 25.

PMID:
28840598
40.

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.

Goldschmidt H, Lokhorst HM, Mai EK, van der Holt B, Blau IW, Zweegman S, Weisel KC, Vellenga E, Pfreundschuh M, Kersten MJ, Scheid C, Croockewit S, Raymakers R, Hose D, Potamianou A, Jauch A, Hillengass J, Stevens-Kroef M, Raab MS, Broijl A, Lindemann HW, Bos GMJ, Brossart P, van Marwijk Kooy M, Ypma P, Duehrsen U, Schaafsma RM, Bertsch U, Hielscher T, Jarari L, Salwender HJ, Sonneveld P.

Leukemia. 2018 Feb;32(2):383-390. doi: 10.1038/leu.2017.211. Epub 2017 Jul 4.

PMID:
28761118
41.

Comparison of Different Stem Cell Mobilization Regimens in AL Amyloidosis Patients.

Lisenko K, Wuchter P, Hansberg M, Mangatter A, Benner A, Ho AD, Goldschmidt H, Hegenbart U, Schönland S.

Biol Blood Marrow Transplant. 2017 Nov;23(11):1870-1878. doi: 10.1016/j.bbmt.2017.07.015. Epub 2017 Jul 25.

PMID:
28754546
42.

Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice.

Baertsch MA, Hillengass J, Blocka J, Schönland S, Hegenbart U, Goldschmidt H, Raab MS.

Hematol Oncol. 2018 Feb;36(1):210-216. doi: 10.1002/hon.2462. Epub 2017 Jul 7.

PMID:
28685863
43.

Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts.

Meziane I, Huhn S, Filho MIDS, Weinhold N, Campo C, Nickel J, Hoffmann P, Nöthen MM, Jöckel KH, Landi S, Mitchell JS, Johnson D, Jauch A, Morgan GJ, Houlston R, Goldschmidt H, Milani P, Merlini G, Rowcieno D, Hawkins P, Hegenbart U, Palladini G, Wechalekar A, Försti A, Schönland SO, Hemminki K.

Haematologica. 2017 Oct;102(10):e411-e414. doi: 10.3324/haematol.2017.171108. Epub 2017 Jul 4. No abstract available.

44.

Meeting report of the 6th Heidelberg Myeloma Workshop: current status and developments in diagnosis and therapy of multiple myeloma.

Merz M, Raab MS, Goldschmidt H, Hillengass J.

J Cancer Res Clin Oncol. 2017 Dec;143(12):2521-2526. doi: 10.1007/s00432-017-2463-x. Epub 2017 Jun 26.

PMID:
28653099
45.

Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach.

Went M, Sud A, Law PJ, Johnson DC, Weinhold N, Försti A, van Duin M, Mitchell JS, Chen B, Kuiper R, Stephens OW, Bertsch U, Campo C, Einsele H, Gregory WM, Henrion M, Hillengass J, Hoffmann P, Jackson GH, Lenive O, Nickel J, Nöthen MM, da Silva Filho MI, Thomsen H, Walker BA, Broyl A, Davies FE, Langer C, Hansson M, Kaiser M, Sonneveld P, Goldschmidt H, Hemminki K, Nilsson B, Morgan GJ, Houlston RS.

Blood Cancer J. 2017 Jun 16;7(6):e573. doi: 10.1038/bcj.2017.48. No abstract available.

46.

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study.

Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X, Beksac M, Alsina M, Oriol A, Cavo M, Ocio EM, Mateos MV, O'Donnell EK, Vij R, Lokhorst HM, van de Donk NWCJ, Min C, Mark T, Turesson I, Hansson M, Ludwig H, Jagannath S, Delforge M, Kyriakou C, Hari P, Mellqvist U, Usmani SZ, Dytfeld D, Badros AZ, Moreau P, Kim K, Otero PR, Lee JH, Shustik C, Waller D, Chng WJ, Ozaki S, Lee JJ, de la Rubia J, Eom HS, Rosinol L, Lahuerta JJ, Sureda A, Kim JS, Durie BGM.

Leukemia. 2017 Nov;31(11):2443-2448. doi: 10.1038/leu.2017.138. Epub 2017 May 12.

PMID:
28620163
47.

[Current Aspects in Diagnosis and Therapy of Plasma Cell Myeloma].

Bärtsch MA, Goldschmidt H.

Dtsch Med Wochenschr. 2017 Jun;142(11):800-804. doi: 10.1055/s-0043-100295. Epub 2017 May 31. German.

PMID:
28564730
48.

AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis.

Dittrich T, Bochtler T, Kimmich C, Becker N, Jauch A, Goldschmidt H, Ho AD, Hegenbart U, Schönland SO.

Blood. 2017 Aug 3;130(5):632-642. doi: 10.1182/blood-2017-02-767475. Epub 2017 May 26.

PMID:
28550043
49.

Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up.

Hegenbart U, Bochtler T, Benner A, Becker N, Kimmich C, Kristen AV, Beimler J, Hund E, Zorn M, Freiberger A, Gawlik M, Goldschmidt H, Hose D, Jauch A, Ho AD, Schönland SO.

Haematologica. 2017 Aug;102(8):1424-1431. doi: 10.3324/haematol.2016.163246. Epub 2017 May 18.

50.

Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation.

Xu J, Pfarr N, Endris V, Mai EK, Md Hanafiah NH, Lehners N, Penzel R, Weichert W, Ho AD, Schirmacher P, Goldschmidt H, Andrulis M, Raab MS.

Oncogenesis. 2017 May 15;6(5):e337. doi: 10.1038/oncsis.2017.36.

Supplemental Content

Loading ...
Support Center